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Neuronal development, function, and the subsequent degeneration of the brain are still an enigma in both the
normal and pathologic states, and there is an urgent need to find better targets for developing therapeutic
intervention. Current techniques to deconstruct the architecture of brain and disease-related pathways are
best suited for following up on single genes but would take an impractical amount of time for the leads
from the current wave of genetic and genomic data. New technical developments have made combined
high-throughput-high-content (HT-HC) cellular screens possible, which have the potential to contextualize
the information, gathered from a combination of genetic and genomic approaches, into networks and func-
tional biology and can be utilized for the identification of therapeutic targets. Herein we discuss the potential
impact of HT-HC cellular screens on medical neuroscience.Introduction
Although human genome research is still a very young discipline,
it already plays a central role in biomedical research aimed at
understanding the molecular mechanisms underlying human
(disease) phenotypes. Since the discovery in the 1980s that
DNA polymorphisms could be used to create genetic linkage
maps (Botstein et al., 1980), they have become an essential
tool for gene discovery and are instrumental for the identification
of many pathogenic mutations for human diseases. Currently,
pathogenic mutations for human disorders in thousands of
genes have been identified by linkage and positional cloning
approaches, including genes, among many others, for neurode-
generative disorders such as the Amyloid Precursor Protein
(APP) and Presenilin (PS1 and PS2) genes for familial forms of
Alzheimer disease (AD), or the a-synuclein and Leucine-rich
repeat kinase 2 (LRRK2) genes for Parkinson disease (PD)
(Bettens et al., 2010; Cookson and Bandmann, 2010). The
subsequent functional characterization of the causative genes
has significantly increased our understanding of pathogenic
mechanisms of disease and is continuously providing us with
new starting points for research toward better therapeutic
approaches.
Encouraged by these successes and by the quickly evolving
methodologies to study DNA variation on a genome-wide scale,
human genome research has shifted from identifying and
characterizing single genes for Mendelian disorders toward
more complex and multifactorial diseases in which tens to
hundreds of genetic and environmental risk factors play a role.
This shift of attention is nicely illustrated by the recent wave of
genome-wide association studies (GWAS) that has revealed
large numbers of often relatively small risk factors for multifacto-
rial neurodegenerative diseases such as AD, PD, and amyo-
thropic lateral sclerosis but also for mental illnesses such as
schizophrenia, bipolar disease and autism (Hindorff et al.,2010). Much of this progress wasmade possible by the develop-
ment of high-density arrays for SNP genotyping. Similar to SNP
arrays, array-based analyses of gene expression, regulatory
sequences, and proteins have been developed and are widely
used. The breakneck speed of technological developments in
genomics is demonstrated by the recent developments in the
field of sequencing. Next-generation or massive parallel
sequencing (MPS) of whole-exome DNA is quickly replacing
classical linkage studies (Biesecker, 2010; Krawitz et al., 2010;
Ng et al., 2010), and, similarly, new MPS-based sequencing of
RNA instead of microarrays has the clear advantages that
it can measure expression variation on a genome-wide level
and is less biased by the selection of content like microarrays
(Metzker, 2010). MPS can easily be combined with other
genome-wide techniques to detect epigenetic changes such
asmethylation (MeDIP-seq) (Laird, 2010) or DNA-protein interac-
tions like transcription factor binding (ChIP-Seq) (Park, 2009).
Just a few years after the introduction of the first-generation
sequencers of this kind, a new generation, some able to
sequence single molecules without amplification steps, has
already entered the market, making whole-genome sequencing
on a large scale feasible (Metzker, 2010). These technical devel-
opments have changed the field of human genetics and have
contributed to the successes of the field. As a consequence,
a considerable part of the heritability of complex diseases can
now be explained although the majority of genetic factors still
remains to be identified (Manolio et al., 2009).
The discussion of how to find these remaining genetic risk
factors, often referred to as ‘‘missing heritability,’’ is largely
based on statistical arguments geared toward increased statis-
tical power to detect a genetic risk factor (Maher, 2008; Manolio
et al., 2009). As a result, increasingly large study samples are
being genotyped or used for large-scale targeted resequencing
to detect rare genomic variants with small effect sizes. WhileNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 207
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final solution. To really move forward and fully understand
genetic risks and use this knowledge for therapy development,
we need to think how we can use biology to help dissect
the genetic risk factors for human disorders. For example,
genetic association studies generally test for the association of
a clinical phenotype with a single genomic variant at a time
(usually a single-nucleotide polymorphism, or SNP) and repeat
this test for all SNPs tested. This method is very powerful to
detect the effect of a single risk factor for a phenotype, and by
combining p values from different SNPs one can detect the
additive effect of multiple risk factors. However, from biology it
is clear that genes do not act by themselves but that they func-
tion in gene networks and molecular pathways and that their
actions are often not simply additive but often epistatic. The
use of single SNP association tests is therefore an oversimplifi-
cation of the biological situation because these epistatic effects
will not be detected. In addition, the biological effect of single
genes is exerted on a single pathway, but often they function
in several distinct pathways with temporal and tissue-specific
regulation. It is therefore important to widen our attention to
gene networks. We and others are developing statistical
methods to detect joint (both additive and epistatic) effects of
genes in genetic data (Bochdanovits et al., 2008; Cordell,
2009; Ruano et al., 2010).
Although there has been remarkable success in identifying
genes for Mendelian disorders and we now seem to be able to
identify reproducible (although relatively small) risk factors for
complex diseases, the translation of genetic knowledge to effec-
tive therapy has, in our opinion, been disappointingly slow. The
available treatment options for most neurological and neurode-
generative diseases are not curative, and successful medica-
tions like L-DOPA for PD have not been developed based on
genetic findings. In this we feel that genetics has not yet fulfilled
its promise for faster therapy development, and it is important to
realize what the reasons are for this lack of translation.
The identified genetic risk factors for Mendelian diseases are
attractive leads for developing treatments because they act at
the very start of the pathogenic process; however, the genes
themselves are often not the most suitable targets for drug
development. Many of the mutated products turn out to be
difficult to modulate using chemicals compounds, or they act
in multiple pathways complicating the development of effective
medication with high efficacy and specificity but importantly
also with limited side effects. For example, the LRRK2 gene is
an important risk factor for PD. At first glance the gene seems
an excellent candidate for developing a chemical compound
as the mutations are dominant gain-of-function mutations of its
kinase activity. However, even in this case, developing a suitable
compound is a daunting task. The gene is widely expressed in
brain and other tissues, during both development and adult
life, which complicates the development of a compound that
affects only its activity in the relevant brain area and that has
no off-target effects on other kinases. On the other hand, even
if the identified risk factors might not be the most suitable drug
targets themselves, they do point to molecular pathways that
are at the basis of the pathogenesis of disease. Therefore, treat-
ment strategies targeted at other key gene products in the same208 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.affected pathways, which might be easier to target or have
a higher specificity, could lead to more successful therapeutic
approaches. Consequently, a systematic functional character-
ization of genes within the context of their molecular pathways
is essential for the translation of genetic findings toward therapy.
For multifactorial diseases, an even more complex situation
exists. GWAS are not designed to directly identify the relevant
biological variant, but, similar to linkage studies, they point to
a location of the genome where a risk variant is located. This is
because GWAS test only a selection of genome variants, usually
in the range of 500,000 to 1 million SNPs under the assumption
that they capture the information of all other variants of the
genome. This assumption, based on the concept of linkage
disequilibrium (LD) or the nonrandom association of alleles at
two or more loci (usually physically close), allows to reduce the
number of SNPs to be tested because if two SNPs are in high
LD, testing one SNP will provide information on the genotype
of the other SNP. It is therefore possible to test for all genetic
variation without genotyping every SNP in a chromosomal
region. A drawback is that, because only a small proportion of
genomic variation is actually tested, the chances that the biolog-
ically relevant variant is tested are small and that the subsequent
identification of the biologically relevant mutation located under
the association peak is often problematic because the functional
annotation of the human genome is very limited. Unfortunately,
the current information in the genome databases is still heavily
biased toward protein coding genes that have been extensively
studied in classical molecular and cell biological experiments,
but we have very little knowledge about the possible function
of the remaining 98% of our genome, which consists of noncod-
ing DNA. The ENCODE and FANTOM projects have given us
a first glance at how complex our genome really is (Birney
et al., 2007; Carninci et al., 2005; Katayama et al., 2005). Most
of our genome is transcribed into (noncoding) RNAs of all sorts
and our classical gene models are under discussion. This is
a major problem for interpretation of our GWAS findings since
in most studies the association is found with SNPs that reside
in noncoding regions of genes or in intergenic regions, and it is
unclear what their biological functionality could be. The interpre-
tation of the possible biological consequences of identified risk
variants therefore requires a much better understanding of the
functions of our genome, especially for those located outside
the well-annotated protein coding regions. Considering the
speed at which GWAS and other ‘‘omics’’ data sets are currently
being published, it is obvious that obtaining a full functional
annotation of our genome cannot rely on detailed cell biological
studies on single genes alone. The task would take an imprac-
tical amount of time and work using standard molecular
and cell biological approaches. Because of the scale of the
task and because of the recent technological developments,
functional studies of genes are becomingmore andmore depen-
dent on outcomes of high-throughput (HT) functional genome
analyses. By extending the technological advancements for HT
analysis with the available multidimensional or high-content
(HC) cell biological approaches based on single genes to gene
networks and to a genome-wide scale, we can now identify
modifying genes and molecular pathways of disease-causing
genes as well as dissect components of multifactorial
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methods with HC cellular screens can also aid in the develop-
ment of therapeutic targets and help to understand fundamental
biological processes. We shall present an overview of the impor-
tant aspects of conducting a HT-HC cellular screen and discuss
the possible application of this methodology in medical neuro-
science.
High-Throughput-High-Content Screening
Successful therapy development for neurological disease
requires a thorough understanding of the relationship between
the variation present in our genome and the corresponding
molecular phenotypes in relation to clinical phenotypes. As
discussed above, the functional annotation of the human
genome is a major bottleneck in this process, but in addition
there is a lack of ‘‘connectivity’’ with pathways for most of the
genes in the genome because we have little knowledge about
most genes’ functional interactions. This lack of information
makes it such that many of the genetic variants we identify as
associated with a disease cannot be evaluated for their role in
their proper molecular environment. Interactions between genes
are often subtle and complex and require a multidisciplinary
approach in which genomic information, gene and protein
expression levels, and cell biological parameters are integrated.
The ability to collect this information rapidly and inexpensively
has long been a bottleneck to realizing this goal. However,
in recent years genomic approaches have entered a functional
evaluation phase, and newly developed HT methods now
provide enormous amounts of raw data for that purpose
(Fan et al., 2006).
The first HT screens (HTS) were developed within the pharma-
ceutical industry and were the mainstay of drug discovery
(Hertzberg and Pope, 2000). In this context, HTS conduct
thousands to millions of biological tests to identify compounds,
genes, or molecules that are involved in a biological process.
Initial assays measured the effect of compounds on purified
enzyme activity, on interactions between proteins, or on
molecules by using fluorescence, luminescence, or absorbance
readouts in simple ‘‘mix and measure’’ assays (Inglese et al.,
2007a; Macarron, 2006; Macarro´n and Hertzberg, 2009). These
assays have the advantage that any hit identified has a known
target, and in combination with advancements in robotics,
automation, and assay miniaturization, investigators can screen
tens of thousands of different modifiers without bias. This
approach has been successful in identifying for example protein
kinase inhibitors (Aherne et al., 2002); however, many of the
compounds or modifiers identified in vitro could not be
confirmed in ex or in vivo systems (Houston et al., 2008; Zhang
et al., 2000). As a consequence, alternative methodologies,
requiring an intact biological system, have been pursued in
which research questions focused more on understanding the
interactions between different cellular processes or the function
of unknown genes. Sincemethods to systematicallymodify gene
expression and/or function (e.g., shRNA genome-wide libraries
for RNAi-mediated gene silencing, overexpression libraries) are
now accessible (Grimm, 2004; Maddox et al., 2008; Moffat
et al., 2006) and robotic methods have been developed to allow
the automated large-scale cell culturing of mammalian cells,cell-based HTS has become suitable as an investigative tool to
interrogate the function of a gene, protein, or pathway using
relevant molecular phenotypes within the complex environment
of cells, and to bridge the gap between in vitro and whole-animal
models (An and Tolliday, 2010; Gasparri, 2010; Kumar et al.,
2010; Zhang et al., 2009; Zhang and Heyse, 2009).
However, to date, most HT cell-based screens have been
whole-well cell assays that quantify one molecular event or
use simplistic readouts of complex biological process (e.g.,
measurement of apoptosis by measuring only caspase 3 activa-
tion or measuring cell proliferation by the reduction of the
tetrazolium salt MTT)—they have been one-dimensional. While
these can be excellent phenotypes to study the effects of
compounds or genes on, for example, tumor growth, for neuro-
logical diseases they will probably miss subtle but essential
effects or changes that are present only in a subset of cells,
as is often the case for neurological disorders. To better under-
stand how genes, networks, and environmental factors coop-
erate to regulate the complex phenotypes in the brain, one has
to move from one-dimensional to multidimensional or multipara-
metric HC phenotypes. HC cellular screens have become
feasible after the development of high-quality fluorescent and
confocal microscopes including advanced analysis software
(for example the Cellomics ArrayScan from Thermo Scientific)
and with regard to understanding the complexity of biological
processes, has several advantages compared to whole-well
HTS (Clemons, 2004; Conrad and Gerlich, 2010; Megason and
Fraser, 2007). The simultaneous quantification of several
different processes provides multiple avenues for identifying
modifiers of accessible and biologically relevant targets and
can thus facilitate identification of gene interactions or improve
detection of drug compounds with potentially harmful side
effects. In addition, structures or processes that could not be
quantified by whole-well HT screens, such as axonal and
dendritic growth, can be visualized and quantified with relative
ease (Sepp et al., 2008).
Multiparametric data generated by HCS may also provide
information about temporal and spatial changes, thus enabling
a more sophisticated understanding of responses in the cell to
multiple perturbations. This was elegantly illustrated by a recent
study (Miller et al., 2010) using the mutant Huntington protein
(HTT). With the use of HCS, authors were able to demonstrate
that within a cell, formation of inclusion bodies (IB) was
correlated with reduced diffuse (free, nonaggregated) mutant
HTT levels and with improved cell viability. The demonstration
of this relationship would not have been possible using conven-
tional HTS as one would not have assayed for both IB formation
and diffuse HTT levels. In addition, if using a whole-well measure
of apoptosis, one would simply observe cell loss and would miss
the relationship between IB formation and maintenance of cell
viability in a subset of cells.
Unfortunately, HC cellular screens aremore expensive and are
difficult to establish and conduct on a large scale because of the
simultaneous labeling and quantification of several features and
the experimental variation one has to deal with when using
mammalian cells. However, as technology for automated cell
culture, imaging, and algorithms for image analysis is improving,
the gap between HCS and HTS is decreasing as many assaysNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 209
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reproducibility, and economic feasibility for HTS screening
(Maddox et al., 2008).
Experimental Design
To conduct a HT-HC screen and ensure that meaningful data are
collected, several aspects have to be considered and optimized.
Once a testable hypothesis or biological question has been
decided, an assay to monitor the biological process or protein
of interest has to be designed. This is one of the most important,
time-consuming, and complex aspects of a HT-HC screen, but
a high-quality assay for a relevant cellular phenotype is essential
for a meaningful screen. An assay is either a biochemical or
cellular experiment that provides a qualitative or quantitative
measure of a compound, gene, or other molecule (An and
Tolliday, 2010; Clemons, 2004; Maddox et al., 2008).
Assay Design
There are too many cell-based assays to discuss extensively
within this review (Figure 1), but with the use of chemicals,
fluorescent proteins, or genetically encoded biosensors it is
possible in principle to quantify virtually any molecular event
within the cell (Daub et al., 2009; Dragunow, 2008; Sato et al.,
2002, 2007; Varma et al., 2007). For example, Sato et al. visual-
ized signal transduction based on protein phosphorylation in
living cells by joining two different-color mutants of green
fluorescent protein (GFP), YFP, and CFP by a tandem fusion
domain composed of a substrate domain for the protein kinase
of interest, a flexible linker sequence, and a phosphorylation
recognition domain that bindswith the phosphorylated substrate
domain (Sato et al., 2002). Intramolecular interaction of the
substrate domain and the adjacent phosphorylation recognition
domain is then dependent upon phosphorylation of the substrate
domain by a protein kinase, which influences the efficiency of
fluorescence resonance energy transfer (FRET) between the
GFPs. The assay was originally designed to visualize protein
phosphorylation by the insulin receptor but can also be adapted
for other proteins, for example, the phosphorylation of a-synu-
clein at Serine 129, which is possibly an early event leading
toward a-synuclein aggregation (Chen and Feany, 2005;
Gorbatyuk et al., 2008).
To build reliable assays of this kind not only requires excellent
molecular biology skills but is also time consuming and a major
bottleneck for performing HT-HC cellular screens. Reliability of
the measurement is paramount, and as many of the phenotypes,
both natural and diseased, will be the result of large numbers of
genes functioning in networkswith additive and epistatic interac-
tions, screens should be able to detect such subtle effects.
The assay should be able to quantitatively report on the pheno-
type of interest and be robust with low variability and high signal-
to-noise ratio. It must have low false-positive and -negative
rates, be highly reproducible, and be sensitive (Birmingham
et al., 2009; Coma et al., 2009; Malo et al., 2006). The Z0 factor
is an often used way to estimate assay quality and is calculated
as a signal detection window between positive and negative
controls scaled by the dynamic range (Zhang et al., 1999).
The ‘‘better’’ an assay is, the lower the risk of false positives
and negatives. To assess the false-positive and -negative rates,210 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.an assay validation should be performed (Macarro´n and Hertz-
berg, 2009). Assay validation consists of a screen containing
a representative sample of the screening collection and is
conducted in the same way as the actual screen would be
performed. Performing the assay validation allows the empirical
determination of error rates (Brideau et al., 2003; Zhang and
Heyse, 2009), spatial effects (Root et al., 2003), systematic
handling errors, and optimal methods for data analysis (Birming-
ham et al., 2009; Macarro´n and Hertzberg, 2009; Makarenkov
et al., 2007; Marazı`a et al., 2008). If during the assay validation
it is not possible to reliably, robustly, and reproducibly detect
the modifiers, it would be necessary to reoptimize the screening
procedure and possibly the assay itself (Echeverri and Perrimon,
2006). Excellent reviews that discuss these issues in more detail
are available (Inglese et al., 2007b; Stone et al., 2007).
Once the assay is built, it is miniaturized to allow the high-
throughput administration of thousands of compounds or gene
modifiers (for example by RNAi or overexpression) and to mini-
mize cost. During the screen, one has to identify true ‘‘hits’’ while
minimizing error rates by replication experiments and specific
molecular biology approaches (Figure 2). The integration of
HC-HT data with information generated from other ‘‘omic’’
approaches can help to construct a multidimensional or
‘‘systems biology’’ overview of the role of ‘‘hits’’ within the cell.
Model Systems
An additional layer of complication arises in selecting the appro-
priate model system in modeling brain diseases. The brain is our
most complex organ and consists of different highly specialized
cell types that function in a highly integrated way. Single neurons
can communicate with tens tomany thousands of other neurons,
and as many as 1015 synapses may exist. In contrast to other
organs, the main functions of the brain are performed by highly
specialized cells that cannot renew themselves by cell division
and therefore have to be resistant to a lifetime of insults while
performing tasks that require large amounts of energy resulting
in a high metabolic rate. For modeling such a complex system,
a mammalian animal model comes closest to the desired situa-
tion, but using whole organisms limits research to specific ques-
tions for obvious logistic reasons. Thus one has to develop
representative, standardized ex vivo cell culture models to allow
the reliable detection of subtle effects as well as to conduct
screens on the scale that it is necessary to deliver targets with
the speed and accuracy that is needed. Choosing the best cell
type for a particular HC assay is challenging as each option
comes with inherent benefits and drawbacks. The decision will
largely depend on (1) whether themodel is a good representation
of the phenotype or mechanism under investigation, (2) the
method by which one wants to monitor a cellular phenotype,
(3) the method by which one wants to perturb the genes (viral
transduction, chemical compounds), and last but not least (4)
the scale of the experiments (whole-genome screens versus
gene subsets). By necessity, the larger the experiment the easier
the model has to be to culture and expand to the numbers that
are needed for the experiment. Thus at present for most large-
scale experiments, such as genome-wide shRNA screens,
neuroblastoma cell lines are the primary choice with more
complex models such as primary neurons being reserved for
Figure 1. Examples of HT-HCS Assays for a Variety of Cellular Processes
With the modern molecular biology tools that are available, one can genetically or chemically modify a cell and monitor the consequences by using a range of
assays.
(A) Phosphorylation of histones in response to chemical treatment of cells.
(B) Alterations in methylation patterns on a genome-wide scale (adapted from Gibbs et al., 2010). This figure represents the comparison of methylation patterns
between different brain regions.
(C) Whole-genome microarray to monitor changes in gene expression.
(D) One canmodify the cell and determine the pathways controlling the localization of specific RNA transcripts by using fluorescent ribo-probes. Nuclei staining is
in blue and RNA staining is in red.
(E) Using fluorescently tagged proteins one can monitor the folding and aggregation of specific proteins, which is a common pathogenic mechanism observed in
neurodegenerative diseases. The image shows the aggregates of the SNCA protein (green) and nuclei (blue).
(F) One can monitor specific posttranslational modifications and determine the pathways that control this modification. If the modification is an important part of
the pathogenic processes, one can utilize this information to identify suitable therapeutic targets. The image shows immunostaining for total SNCA (red) and
phosphorylated SNCA (yellow).
(G andH) Assays conducted inwhole organisms can be useful to study processes that are not possible ex vivo or in humans such as nervous systemdevelopment
in (G) Caenorhabditis elegans (staining of all neuronal cells) and (H) Drosophila melanogaster (staining for two RNA species, bHLH and cato, involved in neuronal
development) (adapted from zur Lage and Jarman, 2010).
(I and J) One can monitor synaptogenesis between pre-and postsynaptic junctions (I) in primary neuronal cocultures and (J) synapse formation on hippocampal
DIV12 neurons labeled with synapsin1 (green) and MAP2 (red) (image courtesy of Desiree Schut and Matthijs Verhage).
(K) HCS assay for determining modulators of apoptosis (simultaneous staining for nuclei, mitochondria, F-actin, and Beta III tubulin).
(L) Labeling of synaptic vesicles using a synthetic construct of NBEAwith egfp, duf, ph, and beach domains andMAP2 (blue) (image courtesy of Juliane Lauks and
Matthijs Verhage). All the assays can be multiplexed to obtain a multidimensional perspective of either gene function or detect side effects in drug compounds
screens. Data from all the different assays in combination with genemodification can subsequently be integrated to obtain a systems biology overview of the cell.
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follow-up (Boutros and Ahringer, 2008; Daub et al., 2009; Eche-
verri and Perrimon, 2006; Eglen et al., 2008a, 2008b).
Yet, in the living brain, multiple highly specialized cell
types function together within blocks of tissue. In contrast, the
current ex vivo models, including primary cells, are essentially
two-dimensional (2D) and thus do not represent the 3D in vivosituation where different cell types are embroiled in complex
cell-to-cell and cell-to-matrix interactions. The architecture and
morphology of these structures can have a profound impact on
the behavior and gene expression of the cell types involved
(Thomas et al., 2002). Thus methods are being developed to
reconstruct the in vivo 3D architecture in an ex vivo environment
(Kim, 2005; Kim et al., 2004; Kunz-Schughart et al., 2001; 2004).Neuron 68, October 21, 2010 ª2010 Elsevier Inc. 211
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Figure 2. Workflow for Conducting a HT-HCS Screen
From left to right: the first step of HT-HCS includes the choice of an appropriate library and the development of relevant cellular assays for the scientific question to
be answered. This is followed by the production of assay plates with the cultured cells of choice, either transfected with the library of choice or treated with
a compound library. The next step consists of HCS imaging for the relevant cellular phenotypes and the data analysis of primary data (i.e., flagging which
compounds are giving a positive response in the assay, namely hit identification). Hit identification includes primary and secondary screens to confirm hits.
Follow-up experiments for identified hits can be designed. In the case of compound screens, adsorption distribution, metabolism, elimination, and toxicity testing
(ADMET) will be done. In the case of functional evaluations or network approaches, more detailed molecular studies, bioinformatic network pathway analysis,
data integration, or other experiments can be performed.
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more standardized, and advances in imaging and image analysis
with automated microscopes have to be realized. Microscopes
should image through several Z heights and subsequently
compile the images to extract the information with the pace
that is necessary to facilitate genome-wide screens. At present,
automated confocal microscopes (for example, Opera,
PerkinElmer) have such capabilities but are limited by their
throughput. With the improvements in technology (Megason
and Fraser, 2007) and 3D image reconstruction and analysis
algorithms, the throughput on such systems is increasing
enabling the future usage of 3D cell cultures in HT-HC screening.
Another system with great potential to model neurological
phenotypes in cell culture are embryonic stem (ES) cells and
induced pluripotent stem (iPS) cells as they combine the
advantages of primary cells with those of cell lines. ES and iPS
cells have the ability to proliferate andcanbe subsequently differ-
entiated, in principle, into any neuronal cell type in very large
quantities (Salero and Hatten, 2007; Smidt and Burbach, 2007).
This is an extremely exciting approach as this could potentially
give rise to an endless supply of human neuronal cells. In addi-
tion, these cells might allow us to more realistically model multi-
factorial diseases than currently possible. For multifactorial
disorders, the effect of single gene variants will often be small
and subtle and will probably not result in a visible or testable
phenotype by itself. Also modeling such a risk factor by simple
gene knockout, knockdown, or overexpression might induce
severe phenotypes that do not mimic the natural situation. To
construct a cellular model that incorporates the realistic effect
size of all identified risk factors, likely to be tens to hundreds, is
impractical. Therefore, methods to study combinations of risk212 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.factors or gene networks are needed. With the discovery that
human fibroblasts can be genetically reprogrammed into iPS
cells (Takahashi et al., 2007; Takahashi and Yamanaka, 2006)
and redifferentiated into neurons that can retain biochemical
and pathological deficits of a given disease (Ebert et al., 2009;
Marchetto et al., 2010; Park et al., 2008) aswell as form functional
neurons in vivo (Wernig et al., 2008), HT-HCS could use patient-
specific cell lines to model multifactorial diseases. Although the
potential of ES and iPS cells in HT-HCS is promising, their use
is limited at present as protocols to differentiate ES and iPS cells
into neuronal cells are costly, requiring large numbers of growth
factors; inefficient with great variability in composition of the final
culture that is formed; and labor intensive. For ES and iPS to be
used in HT-HCS, methods will need to be developed that
improve, standardize, and automate their culture and differentia-
tion into consistent and pure populations of specific neuronal
types. The neuronal types that can be formed will also need to
be characterized in much more detail in terms of expression,
epigenetic modifications, and functionality to determine how
accurately they represent neurons in vivo.
Outlook
The development of automated high-resolution fluorescent and
confocal microscopy and their integration into automated neu-
ronal culturing systems has finally brought cell biology into the
domain of other ‘‘omic’’ sciences (Cellomics). With the range of
assays that can be built and the acquisition of multidimensional
phenotypes (Daub et al., 2009; Dragunow, 2008; Thomas, 2010),
the number and the scale of questions that can be asked and
answered has increased tremendously. This is not an overstate-
ment, as was shown by a recent genome-wide siRNA screen
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study screened for modifier genes of the circadian clock.
Expression of relevant genes follows a rhythmic pattern, and to
follow this pattern the authors used a kinetic bioluminescence
assay linked to the promoters of the Bmal1 or Per2 genes, which
are important genes in regulation of circadian rhythm, as a proxy
for their expression. Knockdown of nearly 1,000 genes reduced
rhythm amplitude, and several hundreds of genes increased
amplitude Characterization of a subset of these genes demon-
strated a dosage-dependent effect on oscillator function.
Protein interaction network analysis showed that dozens of
gene products directly or indirectly associate with known clock
components. The study elegantly demonstrated that genome-
wide screens using complex phenotypes that are relevant in
neuroscience have become feasible, even though the study
was still performed using manual cell culturing. For screening
multiple phenotypes simultaneously and to increase throughput
and sensitivity, automated cell culture combined with high-
content imaging could be used. For example, classic genome-
wide enhancer-suppressor screen for protein aggregation of
mutant a-synuclein using a genome-wide shRNA library (TRC1
library, approximately 110,000 clones)(Moffat et al., 2006), in
our own fully automated cell culture and imaging set-up, using
cellular phenotypes such as protein aggregation, phosphoryla-
tion, protein translocation, neurite outgrowth, mitochondrial
integrity, and cell viability simultaneously, can be performed in
a few months once suitable assays have been build.
High-throughput techniques for generating and analyzing
‘‘omics’’ data have yielded new insights into neurons, such as
thediscoveryof novelgenes, regulatorymechanisms, andprotein
complements (GeschwindandKonopka,2009).However, there is
an inherent risk of predicting phenotypic effects from existing
‘‘omics’’ dataas they require assumptionsaboutgeneandprotein
functions and interactions, prohibiting the identification of novel
essential players since most of our genome is not very well func-
tionally annotated and interactions are mostly unknown. Once
correlations were identified between integrated data sets
(Ge et al., 2003;Walhout et al., 2002), the effect on different path-
ways was predicted and experimentally verified on a gene-by-
gene basis. HT-HC screens now allow the correlation and verifi-
cation of genome-wide genetic screens, mRNA expression, and
quantitative proteomics data, using large-scale cell biology
experiments. The concept was elegantly illustrated with two
recent studies which combined published mRNA expression
profiles with data from a genetic screen in S. cerevisiae to build
cellular response networks associated with a-synuclein toxicity
(Gitler et al., 2009; Yeger-Lotem et al., 2009). With the availability
of HT-HC screening systems for mammalian cells, not only can
these findings now be verified, but screens of a similar size can
be directly performed in a mammalian cellular model using
phenotypes relevant for neuronal function or neurodegenerative
diseases. Furthermore, one is not limited to a simple phenotype
as toxicity but could simultaneously measure effects on a-synu-
clein phosporylation, aggregation, and phenotypes based on
morphology such as neurite outgrowth or other phenotypes rele-
vant for disease pathogenesis.
How can these developments be used to translate genetic
findings into better therapeutic approaches? Genetic studiessuch as linkage and genome-wide association studies point
toward genes and pathways that are involved in the etiology of
disease. After the identification of these factors, researchers
face two main questions: how do these mutations or risk factors
lead to disease? And how can genetic findings be used for
therapy development?
For Mendelian disorders, the classic gene-by-gene experi-
ments have yielded a wealth of data to understand the relevant
biological processes. The large majority of mutations identified
for Mendelian diseases result in amino acid changes, protein
truncations, or alternative splicing defects. However, it is often
unclear how mutation of a gene ultimately leads to a clinical
phenotype such as neurodegeneration. Dissecting the relevant
molecular pathways is essential for our understanding, but by
using classical methods it is laborious and time consuming.
Using a variety of assays in HT-HCS, one will be able to obtain
a complete profile of all upstream regulators (transcriptional
and translation and posttranslational regulators and ncRNAs)
as well as the downstream consequences (e.g., neurite
outgrowth, synapse formation and/or function, protein folding)
of the wild-type and mutant protein (Figure 3) by systematically
testing all combinations of genes within a pathway. For example,
DJ-1 is a gene involved in early onset parkinsonism (Bonifati
et al., 2003) that acts as a sensor and protector for oxidative
stress. In the past years, large numbers of studies discovered
other genes that interact with DJ-1 by using a wide range of
techniques. To test for the biological relevance of these reported
interactions, one can perform an enhancer/suppressor screen
by systematically testing the effect of the knockdown by shRNA
of all these genes on the background of a cell line that is deficient
in DJ-1 expression under oxidative stress conditions. This
methodology will enhance our understanding of gene function
with regard to the phenotypes they control or affect as well as
the pathways in which they function and will allow us to
focus on those genes that are most relevant for the disease
pathogenesis.
In contrast, for multifactorial disease, GWAS have revealed
large numbers of risk factors with mild effects that are often
noncoding and have a biological effect that is not obvious. This
will hopefully be partly resolved with the improved annotation
of our genome by projects such as ENCODE and FANTOM (Bir-
ney et al., 2007; Carninci et al., 2005; Katayama et al., 2005).
However, by using a multiparametric cellular readout one has
a much greater chance of detecting functional effects of risk
factors that are more subtle than those found using simple
one-dimensional whole-well readouts (Figure 3). Recent
developments in ES and iPS cells have also opened up
interesting new possibilities for HT-HCS in understanding
multifactorial disorders as it is clear that simple single gene
knockouts or overexpression studies will not do justice to the
complexity of the diseases. Patient-derived iPS cells from nonfa-
milial cases have a more innate cellular background than typical
exogenous expression systems; they thus may provide a more
predictive cell-based screening strategy because these
diseases are the result of tens to hundreds of risk factors that
jointly and in different combinations lead to clinical phenotype.
Yet while ES and iPS are a very promising model system, we
have to be realistic in that the efficiency of the current protocolsNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 213
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Figure 3. Applications of HT-HC Screens
Mutations or risks factors can affect the function of protein at numerous different levels. Screening can be used to identify all pathways that control the transcrip-
tion, translation, and degradation of the protein as well as determine the pathogenic mechanism of mutations or risk factors. Assays that are able to quantify the
specific mechanism of the mutation (e.g., protein aggregation, disrupted alternative splicing) can also be used in drug screening. If the primary mechanism of the
mutation or the protein is not accessible, the identification of the interacting pathways may yield a more suitable target.
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ful level.
At the moment, a pragmatic approach to understanding the
relation of risk factors to disease is to focus on two or three
major factors at any one time and subsequently combine the re-
sulting effects of each separate pathway into a new model. For
example, one could quantify the biological effect of a limited
number of risk factors (e.g., manipulate their expression level,
or function in the cell) followed by a systematic enhancer/
suppressor screen using transient single-gene knockdown or
overexpression. As an additional factor, one could use an envi-
ronmental stress such as oxidative stress. As throughput is
improving, testing all possible combinations of the perturbations
will allow a genome-wide matrix approach to determine hierar-
chies, interactions, and epistatic effects between pathways.
Such a method comes close to a systems biology approach
that seeks to integrate a wide range of high-throughput biolog-
ical studies to understand how biological systems function by
studying the relationships and interactions between various
parts of a biological system (e.g., metabolic pathways, organ-
elles, cells, physiological systems, etc.) and by reducing the
complexity of a network by identifying modules of functionally
related elements.
To answer the second question of how HT-HCS can help to
fulfill the promises of genetics for therapy development, we
need to determine whether the identified genetic risk factors214 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.are appropriate targets for drug development. Typically, a drug
target is a key molecule involved in a particular metabolic or
signaling pathway that is specific to a disease condition or
pathology. The target should be accessible by a chemical
compound to modulate its function. As a result, the most
common drug targets are G protein-coupled receptors (target
of 50% of drugs), enzymes like protein kinases, ligand-gated
and voltage-gated ion channels, and nuclear hormone receptors
(Aherne et al., 2002). In addition to the above, drugs should be
designed in such a way as not to have undesirable side effects.
Many of the identified genetic factors in neurodegenerative
diseases have broad functions that are not limited to the brain.
In fact, many of the genetic factors are ubiquitously expressed
in the body, function in multiple molecular pathways, and there-
fore may not be an ideal target for drug development. The true
value of identified factors might not be their use as a drug target,
but that they act at the very start of the pathogenic process and
point to crucial molecular pathways that are involved in disease.
Targeting other key genes in these pathways, ones that are
perhaps more suitable as a drug target, is therefore an important
alternative strategy to develop therapeutics. As HC analysis can
now be combined with HT, researchers can perform genome-
wide knockdown and overexpression studies to describe new
gene networks and interactions in detail. In combination with
data derived from other ‘‘omics’’ approaches, key genes in the
disease pathways can be assessed for the ability to regulate
Neuron
Perspectivepathogenesis as well as suitability as a drug target. Moreover, as
one is able to monitor several process simultaneously, side
effects of drugs can be detected with greater ease, reducing
the number of compounds that are carried through for optimiza-
tion and adsorption distribution, metabolism, elimination, and
toxicity testing (ADMET) (Aherne et al., 2002; Eglen et al., 2008a).
Although we feel that HT-HCS holds great promise, by itself it
will not be able to provide a complete understanding of all the
dynamic complex interactions in a biological system. In order
to obtain an accurate systems biology perspective, data sets
from individual screens as well as from other ‘‘omics’’ ap-
proaches, such as genomics, transcriptomics, and proteomics,
will need to be integrated as was recently discussed (Geschwind
and Konopka, 2009). To facilitate the integration of data sets,
reliable and validated screen data need to be made publicly
available with detailed descriptions about the screen in a similar
fashion as has been implemented for publication of mRNA
expression data. As yet there are no public repositories or
regulations for making the data publically available, but as
more and more screens are being performed the need for guide-
lines increases. Reporting data should include thorough informa-
tion about the assay with respect to sensitivity, dynamic range,
signal intensity, stability, and validation as well as full
experimental particulars, data collection, and analysis methods
as reviewed by Inglese et al. (2007b) and Stone et al. (2007).
Conclusions
From the early days when only the effect of a compound on
a single or simple mixture of proteins could be quantified, HT
screening has evolved to a situation where one can now gather
vast amounts of detailed information on practically any cellular
process or molecular event, which will greatly expedite our
understanding of complex biological systems. Combined with
continuing advances in molecular tools, cellular models, live-
cell imaging, and data analysis, HT-HC cellular screening will
be able to provide important answers on the function of genes
and gene networks within the cellular matrix that are needed to
improve our understanding of the pathogenesis of neurological
diseases.
HT-HC cellular screens can be instrumental in unraveling the
heritability of multifactorial disorders. Part of the ‘‘missing herita-
bility’’ can be identified by searching for epistatic interactions
between genes. Now that statistical methods to detect such
interaction are being developed, HT-HC screening can provide
the functional validation of these interactions. HT-HC cellular
screens can thus form an important link between genetics and
genomics and more detailed studies on a cell biological
(single-molecule) level by providing functional validation of
predicted effects for the wealth of HT data from GWAS studies
and other genomic datasets. On the other hand, although auto-
mated imaging, cell culture, and the availability of genome-wide
RNAi resources have made genome-wide high-resolution
cellular screens possible, its success is highly dependent on
the quality and resolution of the assays that are built. The basis
for such assays must be provided by detailed cell and molecular
biological studies, and the integration of all these approaches
can finally provide a better translation of genetic findings into
better targets for therapy development.ACKNOWLEDGMENTS
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